EC approves AstraZeneca’s Tagrisso
London | 05 February 2016

The European Commission has granted conditional marketing authorisation for AstraZeneca’s lung cancer treatment Tagrisso (osimertinib).

AstraZeneca’s Tagrisso is the first medicine to be approved under the European Commission’s expedited process, which aims to speed up the authorisation of drugs that are of major public interest or for which there is unmet need.

Tagrisso reportedly took just over two years to go from human trials to approval.

The drug is specifically indicated for patients with T790M mutation-positive non-small lung cancer, irrespective of previous treatment with epidermal growth factor receptor.

Sean Bohen, chief medical officer at AstraZeneca, said: “The European Commission’s expedited approval reflects the importance of this innovative medicine for addressing the needs of patients with lung cancer who have the T790M mutation.”

“We are now building on our understanding of the clinical activity of osimertinib to explore its full potential in patients with EGFRm lung cancer in multiple treatment settings.”

Author: Tammy Facey

More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization